Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8+NKG2D+ AKT Cell Immunotherapy in Pancreatic Cancer
NCT02929797Phase 1Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CD8+NKG2D+ AKT cell in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Disease-free survival at 1 year. Status: unknown.
02
Drugs
CD8+NKG2D+ AKT cell
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02929797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929797.